^(192)Ir核素脑胶质瘤间质内放疗的研究及其临床应用  

STUDY AND CLINICAL APPLICATION OF INTERSTITIAL BRACHYTHERAPY WITH IRIDIUM 192 FOR GLIOMA

作　　者：刘宗惠[1] 袁卓庭[1] 李士月[1] 于新[1] 崔月汉[1] 康静波[1] 于雪[1] 

机构地区：[1]海军总医院

出　　处：《解放军医学杂志》1999年第2期113-114,共2页Medical Journal of Chinese People's Liberation Army

基　　金：海军"九六"重点科研基金

摘　　要：为观察用１９２Ｉｒ后装治疗脑胶质瘤间质内放疗的有效性及其并发症，用皮下荷瘤鼠和脑荷瘤鼠模型行间质内放疗实验，证明在内照射后可抑制肿瘤生长及延长鼠的生存期的可靠基础上，对７２例脑胶质瘤采用１９２Ｉｒ后装机行瘤间质内近距离照射，取得良好疗效。手术无何严重并发症，无死亡。术后随访１～５年，生存率分别为９２％、８２％、７２％、５６％及３２％，表明生存期显著延长。结论：脑深部胶质瘤用１９２Ｉｒ核素瘤间质内高剂量率照射可有效抑制肿瘤生长，控制复发，延长生存期是一种可供选择的有效的方法。To determine the effectiveness and toxicity of interstitial brachytherapy with 192 Ir on the brain malignant gliomas, 72 patients with anaplastic astrocytoma and multiform glioblastoma were treated with stereotactic brachytherapy by using temporary high activity 192 Ir sources. The median survival for patients underwent brachytherapy was 36 months. Survival rates at 1, 2, and 3 years after brachytherapy significantly increased (92%, 82% and 72% respectively). It was suggested that adjunctive treatment of brain malignant tumors with discrete high doses of radiation therapy delivered by 192 Ir brachytherapy might improve local tumor control and prolong survival time.

关 键 词：神经胶质瘤 脑肿瘤 放射疗法 放射性核素 

分 类 号：R739.410.5[医药卫生—肿瘤] R730.55[医药卫生—临床医学]